Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Eton Pharmaceuticals (ETON) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Eton Pharmaceuticals (ETON) over the last 6 years, with Sep 2025 value amounting to -6.07%.

  • Eton Pharmaceuticals' EBITDA Margin fell 1100.00% to -6.07% in Q3 2025 from the same period last year, while for Sep 2025 it was -4.89%, marking a year-over-year increase of 424.00%. This contributed to the annual value of -6.66% for FY2024, which is 289.00% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' EBITDA Margin is -6.07%, which was up 22.12% from -7.79% recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year EBITDA Margin high stood at 45.08% for Q1 2021, and its period low was -754.45% during Q3 2021.
  • For the 3-year period, Eton Pharmaceuticals' EBITDA Margin averaged around -9.28%, with its median value being -7.79% (2025).
  • Over the last 5 years, Eton Pharmaceuticals' EBITDA Margin had its largest YoY gain of 2,261,419bps in 2021, and its largest YoY loss of 24,731,177bps in 2021.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' EBITDA Margin stood at 21.57% in 2021, then slumped by 907bps to 12.50% in 2022, then plummeted by 1,918bps to -6.69% in 2023, then skyrocketed by 1,209bps to 5.40% in 2024, then slumped by 1,100bps to -6.07% in 2025.
  • Its last three reported values are -6.07% in Q3 2025, -7.79% for Q2 2025, and -26.32% during Q1 2025.